| 0 (0%) | 04-24 11:54 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.46 | 1-year : | 5.21 |
| Resists | First : | 3.81 | Second : | 4.46 |
| Pivot price | 3.09 |
|||
| Supports | First : | 3.01 | Second : | 2.51 |
| MAs | MA(5) : | 3.3 |
MA(20) : | 3.11 |
| MA(100) : | 3.69 |
MA(250) : | 2.08 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 91 |
D(3) : | 80.1 |
| RSI | RSI(14): 59 | |||
| 52-week | High : | 5.57 | Low : | 0.37 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ MYO ] has closed below upper band by 6.7%. Bollinger Bands are 22.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.64 - 3.65 | 3.65 - 3.66 |
| Low: | 3.41 - 3.43 | 3.43 - 3.44 |
| Close: | 3.51 - 3.54 | 3.54 - 3.56 |
Wed, 07 Oct 2020
Here's Why Bristol Myers Offered MyoKardia $13.1 Billion - The Motley Fool
Mon, 05 Oct 2020
With buyout of MyoKardia, Bristol-Myers Squibb reaches into heart of Bay Area biotech - San Francisco Business Times - The Business Journals
Mon, 05 Oct 2020
Is Bristol-Myers a Buy After $13.1 Billion Buy of MyoKardia? - TheStreet
Mon, 05 Oct 2020
Bristol-Myers’ $13 Billion Deal for MyoKardia Spotlights Cardiac Drugs - Barron's
Mon, 05 Oct 2020
Bristol-Myers Squibb (BMY) to Buy MyoKardia (MYOK) for $13 Billion - Bloomberg
Mon, 05 Oct 2020
Why Bristol Myers Squibb (BMY) Is Buying MyoKardia (MYOK) For $13.1 Billion - Pulse 2.0
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 27 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 13.8 (%) |
| Held by Institutions | 47.9 (%) |
| Shares Short | 236 (K) |
| Shares Short P.Month | 298 (K) |
| EPS | -0.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.41 |
| Profit Margin | -42.5 % |
| Operating Margin | -39.9 % |
| Return on Assets (ttm) | -34.4 % |
| Return on Equity (ttm) | -83.4 % |
| Qtrly Rev. Growth | 28 % |
| Gross Profit (p.s.) | 0.38 |
| Sales Per Share | 0.69 |
| EBITDA (p.s.) | -0.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -7.23 |
| PEG Ratio | 35.1 |
| Price to Book value | 8.42 |
| Price to Sales | 5.06 |
| Price to Cash Flow | -14.95 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|